Irosustat (STX64) is a potent tricylic coumarin-based sulfamate that irreversibly blocks STS activity, and it has been examined in phase II clinical trials for the treatment of patients with advanced hormone-dependent breast and endometrial cancers (Stanway et al., 2007). This evidence concerns the gene STS and endometrial cancer.